New drugs for the treatment of pancreatic cancer

Share This Post

Ruiwen Zhang and Robert L. Boblitt from the University of Houston have developed a new pancreatic cancer drug. The research was published in the Journal of Cancer Research. The drug targets two genes at the same time, and this breakthrough achievement is of great significance for the treatment of aggressive and deadly pancreatic cancer.

The drug is also expected to become a framework for the development of drugs to treat other forms of cancer or other diseases. Pancreatic cancer occurs when pancreatic cells begin to multiply out of control and develop into lumps, and the resulting cancer cells can invade other parts of the body. Most cancers start in the area of ​​the pancreas that produces digestive enzymes. Symptoms include back or stomach pain, unexpected weight loss, and jaundice (yellow skin). In addition, a person’s urine may appear dark yellow and itchy skin. There are two oncogenes associated with pancreatic cancer. There are two main ways for the drug to inhibit pancreatic cancer. They activate the nuclear factor of T cell 1 (NFAT1) and murine double microparticle 2 (MDM2), respectively. The latter gene regulates a tumor suppressor gene called p53. When there is no tumor suppressor p53, MDM2 can cause cancer. NFAT1 is used to up-regulate the expression of MDM2, thereby promoting tumor growth. Factors related to diet, nutrition and the environment can lead to increased levels of these factors in the cell.

When talking about this discovery, Dr. Zhang said that the clinical needs of new, effective and safe drugs for the treatment of pancreatic cancer have not yet been met. Our findings represent a major advancement in cancer research. He added: “Most drugs only target one factor. We identified a compound that targets two cancer-related genes. “The new drug is a synthetic compound of MA242. The drug can consume two proteins at the same time, thereby improving the tumor killing efficiency.

Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Donor T cells for CAR T cell therapy
CAR T-Cell therapy

Donor T cells for CAR T cell therapy

Donor-derived (allogeneic) CAR T cell therapy provides a scalable, affordable substitute for patient-specific (autologous) treatment, offering “off-the-shelf” therapy for cancer patients. Although difficulties such as graft-versus-host disease (GvHD) and immune rejection are present, developments in gene editing, immune evasion strategies, and universal donor cells are leading the way. With continuous clinical trials and creative approaches, allogeneic CAR T cells may transform cancer therapy, enabling lifesaving treatment to be more accessible and efficient.

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies Experience from China
CAR T-Cell therapy

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Experience from China

China has made significant strides in optimizing chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Key strategies include improving CAR design to enhance efficacy and reduce toxicity, optimizing manufacturing processes for scalability, and refining patient selection criteria. Researchers are integrating novel gene-editing techniques and combination therapies to overcome resistance. Additionally, real-world data from Chinese hospitals emphasize the importance of standardized protocols and cost-effective production for broader accessibility.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟